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Either herpesvirus entry mediator (HVEM,
TNFRSF14) or nectin-1 (PVRL1) is sufficient for
herpes simplex virus (HSV) infection of cultured
cells. The contribution of individual receptors
to infection in vivo and to disease is less clear.
To assess this, Tnfrsf14/ and/or Pvrl1/
mice were challenged intravaginally with HSV-
2. Infection of the vaginal epithelium occurred
in the absence of either HVEM or nectin-1 but
was virtually undetectable when both receptors
were absent, indicating that either HVEM or
nectin-1 was necessary. Absence of nectin-1
(but not HVEM) reduced efficiency of infection
of the vaginal epithelium and viral spread to
the nervous system, attenuating neurological
disease and preventing external lesion devel-
opment. While nectin-1 proved not to be essen-
tial for infection of the nervous system, it is
required for the full manifestations of disease.
This study illustrates the value of mutant mice
for understanding receptor contributions to dis-
ease caused by a human virus.
INTRODUCTION
Viral entry can be mediated by multiple alternative recep-
tors that are expressed in many cell types and tissues,
making it difficult to assess the roles of each receptor in
disease. Mice with gene disruptions have been of limited
use for studying this problem with human viruses because
mice are often resistant to these viruses. However, mice
are susceptible to HSV infection and disease, and mouse
entry receptors are encoded by genes orthologous to the
genes for the human entry receptors (Spear et al., 2000).
Here we describe the use of mutant mice to explore the
roles in HSV disease of two cell surface proteins that
can mediate the entry of HSV-2 into cells.CManifestations of disease caused by HSV infection of
children or adults range from none to mucocutaneous
lesions to meningitis and encephalitis. The virus replicates
in cells of the mucosal or cutaneous epithelium, causing
blisters or lesions often confined to the epithelium. HSV
also enters neurons and is transported to sensory and
autonomic ganglia to establish latent infections. Reactiva-
tion of HSV in neurons results in transport of virus to the
body surface and in recurrent mucocutaneous lesions,
permitting seeding of additional neurons. Occasionally,
the virus can spread to the CNS to cause life-threatening
disease.
HSV is an enveloped DNA virus, the prototype of the
neurotropic a-herpesviruses. Of the dozen or more enve-
lope glycoproteins in the HSV virion, five have a role in viral
entry. Glycoproteins gB and/or gC can mediate the bind-
ing of virus to cell surface heparan sulfate or related gly-
cosaminoglycans (Shukla and Spear, 2001). This binding
is not sufficient for entry, which requires the interaction
of envelope glycoprotein gD with any one of several cell
surface molecules. These include HVEM (Montgomery
et al., 1996), a member of the tumor necrosis factor recep-
tor family; nectin-1 (Cocchi et al., 1998; Geraghty et al.,
1998) and nectin-2 (Warner et al., 1998), cell adhesion
molecules belonging to the immunoglobulin superfamily;
and specific sites in heparan sulfate (3-O-S-HS) generated
by particular 3-O-sulfotransferases (Shukla et al., 1999).
Interaction of any of these receptors with gD is thought
to trigger conformational changes in gD that result in acti-
vation of the fusogenic activity of trimeric gB and/or the
heterodimer gH-gL (Carfi et al., 2001; Fusco et al., 2005;
Heldwein et al., 2006; Krummenacher et al., 2005; Rey,
2006; Spear et al., 2006), resulting in entry by envelope-
membrane fusion.
HVEM and nectin-1 are efficient entry and cell fusion re-
ceptors for both serotypes of HSV, whereas nectin-2 and
3-O-S-HS appear to be less efficient (Lopez et al., 2000;
Shukla et al., 1999). Also, nectin-2 preferentially mediates
entry of HSV-2 and certain mutants of HSV-1 (Lopez et al.,
2000; Martinez and Spear, 2001; Warner et al., 1998),
whereas 3-O-S-HS preferentially mediates entry of HSV-1
(Shukla and Spear, 2001). Mouse forms of these receptorsell Host & Microbe 2, 19–28, July 2007 ª2007 Elsevier Inc. 19
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ities with both HSV-1 and HSV-2 (Yoon et al., 2003), ex-
cept that it has been difficult to document entry activity
for mouse nectin-2 (Martinez and Spear, 2001; Shukla
et al., 1999). Thus, the best candidates for efficient HSV-2
entry receptors in the mouse are HVEM and nectin-1.
Mice in which the gene encoding HVEM (Tnfrsf14) was
disrupted displayed no evident developmental abnormal-
ities but did exhibit enhanced lethal responses to the mito-
gen concanavalin A and increased susceptibility to auto-
immune encephalomyelitis (Wang et al., 2005). HVEM
has two natural ligands. One is a member of the tumor
necrosis factor family, and its binding to HVEM on T cells,
B cells, neutrophils, macrophages, and possibly dendritic
cells can enhance activation and/or differentiation of these
cells (Croft, 2005; Murphy et al., 2006). The other is B and
T lymphocyte attenuator (BTLA), and the binding of HVEM
to BTLA on T cells can repress T cell proliferation and ac-
tivation (Murphy et al., 2006). Although physiological roles
of HVEM have been associated mainly with cells of the
lymphoid system, HVEM is widely expressed in a number
of other cell types, including epithelial, stromal, and endo-
thelial cells (Spear, 2004). Its expression in the nervous
system has not been studied, in part because initial
screens for transcripts revealed little or no expression in
the brain (Hsu et al., 1997; Montgomery et al., 1996).
Mice in which the gene encoding nectin-1 (Pvrl1) was
disrupted were fertile and developed normally, for the
most part, but exhibited delays in attaining adult size
and abnormalities such as microphthalmia (Inagaki et al.,
2005). There are four nectins and five nectin-like mole-
cules, all of which participate in cell junctions of various
kinds, including adherens junctions (Ogita and Takai,
2006). It seems likely that there is redundancy in function-
ality of the members of this family because disruptions in
expression of specific nectins have deleterious effects
on only a limited subset of the junctions in which each mol-
ecule can be detected. Gene disruptions have shown that
nectin-1 and nectin-3 are both required for a specific junc-
tion between pigmented and nonpigmented cell layers in
the ciliary epithelia and for normal development of the
ciliary body of the eye (Inagaki et al., 2005). Moreover,
both nectin-1 and nectin-3 contribute to the formation of
puncta adherentia junctions in the mouse hippocampus
and influence mossy fiber trajectories (Honda et al., 2006;
Mizoguchi et al., 2002). Nectin-1 is widely expressed in a
variety of cell types, including epithelial, stromal, endothe-
lial, and lymphoid cells, and also in many neurons of the
mouse peripheral and central nervous systems (PNS and
CNS) (Haarr et al., 2001). Moreover, antibodies specific
for nectin-1 have been shown to inhibit entry of virus into
cultured human and rodent neurons (Richart et al., 2003;
Simpson et al., 2005).
Mice can be infected by HSV-1 or HSV-2 and provide
useful models for several aspects of HSV disease in hu-
mans. Mice are susceptible to infection via the intravaginal
route during the diestrous stage of the estrous cycle, when
the vaginal epithelium is only a few cell layers thick and not
cornified, but not during other stages when there is exten-20 Cell Host & Microbe 2, 19–28, July 2007 ª2007 Elsevier Inc.sive cornification. Diestrous can be induced artificially by
an injection of progesterone, so that mice do not have to
be staged prior to inoculation. This model of HSV infection
and disease (Parr et al., 1994) is widely used. Virus repli-
cates in the vaginal epithelium, causing lesions, and then
spreads via autonomic and sensory nerves to peripheral
ganglia, including dorsal root ganglia (DRG), paracervical
ganglia, and other autonomic ganglia in the bladder and
rectal walls (Parr and Parr, 2003). Secondary lesions occur
externally, on the perineal skin and surrounding areas.
Clinical symptoms resemble, in some respects, what hu-
mans may experience during severe primary genital infec-
tion with HSV-2. For example, both mice and humans may
experience urinary retention, constipation, and parapare-
sis, as well as internal and external lesions. In mice, virus is
more likely to spread also to the CNS, causing death, par-
ticularly at the doses of virus used in experimental studies.
To investigate the roles of HVEM and nectin-1 in HSV-2
infection and acute disease, we inoculated Tnfrsf14/
and Pvrl1/ mice, double mutants, and wild-type con-
trols with virus via the intravaginal route and monitored
both clinical signs of disease and the spread of virus
from the portal of entry to the PNS and CNS. The results
showed that either nectin-1 (most efficiently) or HVEM
could mediate the infection of cells in the vaginal epithe-
lium and that neither receptor was required for spread of
virus to the PNS and CNS or for lethal consequences of
disease. Nectin-1 was required, however, for the appear-
ance of secondary external lesions, which may result from
horizontal cell-to-cell transmission of infection between
mucosal and skin epithelia or zosteriform transmission
from neurons to skin cells.
RESULTS
Effects of Mouse Gene Disruptions on Clinical Signs
of Disease after HSV-2 Inoculation
Two virus strains were used for inoculation: virulent HSV-
2(333) and a recombinant form of HSV-2(333) in which
a lacZ expression cassette was inserted into an intergenic
region, so that presence of virus in cells and tissues could
be assessed by staining with the b-galactosidase sub-
strate X-gal. Unless otherwise indicated, the inoculating
dose for each virus, designated here HSV-2 and HSV-2/
Gal, was 6 3 105 plaque-forming units (PFU) per mouse
delivered intravaginally.
The mice were examined daily after inoculation, and
clinical symptoms were recorded, including the appear-
ance of external signs of infection such as hair loss, inflam-
mation, and lesions around the vaginal and rectal open-
ings, around the tail base, and down the legs. Symptoms
also included signs of lethargy, abdominal distention,
dehydration, and (rarely) hind-limb paralysis, which were
indicative of impending death. Mice showing these latter
signs in severe form were euthanized. The results are
summarized in the Kaplan-Meier survival plots shown in
Figure 1. The top panels show days without external signs
of disease, and the bottom panels show days remaining
alive.
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Entry Receptors and HSV Disease in MiceFigure 1. Appearance of External Lesions andMortality after Intravaginal Inoculation ofWild-Type,Tnfrsf14/,Pvrl+/, andPvrl/
Mice with HSV-2/Gal or HSV-2
All mice were injected with Depo-Provera 6 days prior to inoculation of virus (6 3 105 PFU per mouse). The mice were examined daily for external
lesions. They were also examined for severe morbidity requiring euthanasia. The day on which external lesions were first noted and the day of death
or sacrifice were recorded for each animal (n = 16–20 mice for each experimental group). In (A), C57BL/6 (+/+) mice are compared with Tnfrsf14/
mice, in which the gene expressing HVEM was disrupted; in (B), littermate controls (both +/+ and Pvrl+/) are compared with Pvrl/ mice, in which the
gene expressing nectin-1 was disrupted. Kaplan-Meier survival analysis was performed using the Gehan-Breslow test. Statistically significant differ-
ences between mice of different genotypes are noted on the relevant panels. In (B), the p values shown apply to comparisons of Pvrl/ mice with
either +/+ orPvrl+/ mice except for the survival curves for mice inoculated with HSV-2. In the latter case, a significant difference was noted only for the
comparison between Pvrl/ and +/+ mice (curves linked by line). The closed circles on each survival curve indicate censored data due to death of
mice during the experiment or sacrifice of mice at the conclusion of the experiment. Mice were monitored for at least 21 days, but no changes in status
were noted between 18 and 21 days.Absence of HVEM in the Tnfrsf14/ mice had little or
no effect on the course of acute disease, assessed either
by the appearance of external lesions or by mortality, after
wild-type HSV-2 inoculation. Absence of nectin-1 in the
Pvrl/ mice had significant effects, however. In contrast
to the wild-type control mice or Pvrl+/ mice, which were
statistically indistinguishable in terms of disease symp-
toms, none of the Pvrl/ mice inoculated with HSV-2
showed any signs of external lesions (p < 0.001), despite
more than half eventually dying from the infection. The
survival curve (mortality) for the Pvrl/ mice also differed
significantly from that for the wild-type mice (p < 0.01),
indicating some attenuation of disease in the absence of
nectin-1.
HSV-2/Gal is less virulent than HSV-2 (Figure 1 and sta-
tistical analysis given in the Experimental Procedures).
The mutation that abrogates nectin-1 expression (Pvrl/)
had the expected effect of further attenuating disease
caused by HSV-2/Gal. For the mutation abrogating HVEM
expression (Tnfrsf14/), the somewhat unexpected result
was attenuation of disease with HSV-2/Gal but not with
HSV-2. There was a statistically significant difference
between wild-type and Tnfrsf14/ mice in the timing of
external lesion appearance and number of mice eventually
showing such lesions (p < 0.001).
Mice expressing nectin-1 but not HVEM (Tnfsfr14/
Pvrl1+/), HVEM but not nectin-1 (Pvrl1/), and neither
(Tnfrsf14/Pvrl/) were also challenged with HSV-2 atCa 10-fold higher dose than that used in Figure 1 (6 3
106 PFU per mouse instead of 6 3 105). The higher dose
of virus did not significantly alter the timing or manifesta-
tions of clinical symptoms for the HVEM-expressing and
nectin-1-expressing mice (except that one Pvrl1/
mouse exhibited some inflammation at the vaginal open-
ing without the hair loss and lesions typically observed
around the vaginal and rectal openings, around the tail
base, and down the legs). None of the double mutant
mice (n = 9) showed any signs of disease for more than
21 days (Figure 2).
The results of these challenge experiments demon-
strate that neither nectin-1 nor HVEM is essential for
HSV-2 infection of mice via the intravaginal route, as evi-
denced by symptoms or mortality in 50%–100% of the
mice inoculated. Expression in mice of at least one of these
entry receptors appears to be necessary for disease,
based on absence of any clinical symptoms in the double
mutant mice after virus challenge. Absence of nectin-1
alone delayed death and reduced its incidence but did
not prevent it, whereas absence of HVEM alone had little
effect on disease caused by HSV-2. Strikingly, absence
of nectin-1 completely abrogated external lesions in mice
inoculated with either HSV-2/Gal or HSV-2. For mice that
expressed nectin-1, mortality was never observed in the
absence of external lesions. HVEM-deficient mice inocu-
lated with HSV-2/Gal, but not HSV-2, were partially pro-
tected from the development of external lesions.ell Host & Microbe 2, 19–28, July 2007 ª2007 Elsevier Inc. 21
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Expression of b-Galactosidase from HSV-2/Gal
The question arises from Figures 1 and 2 as to whether
mice failing to show any symptoms of disease had actually
become infected by the inoculated virus. As one measure
of the efficiency of infection of the vaginal epithelium and
spread to the nervous system, wild-type and mutant mice
were inoculated with HSV-2/Gal and sacrificed at various
times after inoculation for the dissection of vaginas, DRG,
spinal cords, and perivaginal skin, followed by staining of
these tissues with the b-galactosidase substrate X-gal.
The extent of lesion development on the vaginal luminal
surface and in nervous system tissue was scored as
described in the Experimental Procedures.
Figure 3 shows examples of stained vaginas photo-
graphed at 24 hr after inoculation with two different doses
of HSV-2/Gal: 6 3 105 and 6 3 106 PFU/mouse. At the
lower dose of virus (Figures 3A and 3B), the viral lesions
were numerous and extensive for wild-type and
Tnfrsf14/ mice but were reduced in number and size
for the Pvrl/ mice. However, mice of all three genotypes
invariably had detectable lesions on the vaginal epithelium
(no lesion scores of 0). For the double mutant mice
(Tnfrsf14/Pvrl/), only rare blue spots (<5 per vagina)
were observed, if at all, at either dose of inoculated virus
(Figures 3A and 3C), whereas there were significantly
increased numbers of lesions for the Pvrl/ mice at the
Figure 2. Appearance of External Lesions and Mortality after
Intravaginal Inoculation with HSV-2 of Nectin-1-Expressing
Tnfrsf14/Pvrl1+/ mice, HVEM-Expressing Pvrl1/ mice,
and Double Mutant Mice
The experiment was done as in Figure 1 except that the mice were
inoculated with ten times the dose of HSV-2 (6 3 106 PFU/mouse).
The single Pvrl1/ mouse that exhibited an external sign of disease
showed some inflammation at the vaginal opening but no hair loss or
external lesions around the vagina, rectum, or tail or down the legs,
as was typical for mice that express nectin-1. Kaplan-Meier survival
analysis was performed using the Gehan-Breslow test. Statistically
significant differences were noted for all pairwise comparisons (p <
0.02) except for Pvrl1/ mice versus Tnfrsf14/Pvrl1/ mice in the
percent remaining free of external lesions (n = 4, Tnfrsf14/Pvrl+/;
n = 13, Pvrl1/; n = 9, Tnfrsf14/Pvrl1/).22 Cell Host & Microbe 2, 19–28, July 2007 ª2007 Elsevier Inc.higher dose. These results show that nectin-1 expression
is associated with efficient infection of the vaginal epithe-
lium, but in its absence, HVEM expression permits infec-
tion, albeit less efficiently. When neither nectin-1 nor
HVEM is expressed, infection of the vaginal epithelium
was extremely limited or not detectable even at high doses
of inoculated virus. These results also indicate that the fail-
ure of some wild-type, Tnfrsf14/, orPvrl/ mice to show
symptoms of disease in Figure 1 was probably not due to
failure of the inoculated virus to initiate infection of the vag-
inal epithelium. On the other hand, failure of double mutant
Tnfrsf14/Pvrl/ mice to show any clinical signs of dis-
ease might be accounted for by failure of the virus to
establish infection via the intravaginal route of inoculation.
Figure 4A shows an example of an X-gal-stained spinal
column from a wild-type mouse inoculated with HSV-2/
Gal. A portion of the image was enlarged to show the
staining of DRG. At several time points following HSV-2/
Gal inoculation, infection of the nervous system (DRG,
attached nerves, and spinal cord) was scored. There
was a significant difference between wild-type littermate
controls and Pvrl/ mice in the lesion scores for days 3,
5, 7, and 9 after virus inoculation (Figure 4B; p % 0.003).
Moreover, spread of virus infection to the PNS and CNS
was detectable by X-gal staining for only a subset of mice
in each Pvrl/ experimental group (numbers in parenthe-
ses in Figure 4B), whereas this spread of infection was
readily detectable in all wild-type mice. Tnfrsf14/ mice
(n = 3 for each time point) had scores indistinguishable
from those of the wild-type mice on days 3, 5, and 9 fol-
lowing inoculation (data not shown).
An example of the typical external lesions caused by
HSV-2 is shown in Figure 5A. Samples of perivaginal
skin were dissected from wild-type mice infected with
HSV-2/Gal to assess the spread of virus infection and dis-
tribution of lesions at the gross (Figure 5B) and histological
(Figures 5C–5F) levels. We failed to observe indications
that infection spread directly and contiguously from the
vaginal epithelium itself to external perivaginal regions but
instead noted isolated X-gal-stained lesions, some quite
distant from the vaginal opening (Figure 5B). Serial sec-
tions of external skin also provided evidence for isolated
microscopic viral lesions, often extending into hair follicles
(Figures 5C–5F), as previously observed (Parr and Parr,
2003).
Tracking of Virus Infection and Spread by Titration
of Infectious HSV-2 in Various Organs
Groups of wild-type, Tnfrsf14/, and Pvrl/ mice were
inoculated with HSV-2 at 6 3 105 PFU per mouse and
sacrificed at intervals following inoculation for removal
of the tissues indicated in Figure 6. Each organ was
weighed and homogenized, and serial dilutions were pre-
pared for quantification of PFU. On day 1, virus was de-
tected only in the vaginal samples, with significantly lower
mean titers for the Pvrl/ mice than for wild-type controls
or Tnfrsf14/ mice. Viral loads declined in the vaginal
samples thereafter. On day 3, maximal mean titers of virus
were detected in the DRG of wild-type and Tnfrsf14/
Cell Host & Microbe
Entry Receptors and HSV Disease in MiceFigure 3. Development of Lesions on the
Vaginal Epithelium at 24 hr after Inocula-
tion of C57BL/6, Tnfrsf14/, Pvrl/, or
Double Mutant Tnfrsf14/Pvrl/ Mice
with HSV-2/Gal
The mice were injected with Depo-Provera as
in Figure 2 and then inoculated with HSV-2/
Gal at 6 3 105 PFU per mouse (A and B) or
63 106 PFU per mouse (C). At 24 hr after virus
inoculation, the mice were sacrificed. The vagi-
nas were removed and split open longitudinally
and then fixed and stained with X-gal to detect
b-galactosidase expressed from an insert in
the viral genome. The extent of staining and
therefore of virus infection was scored on
a scale from 0 (no blue lesions noted) to 5
(greater than 80% of vaginal epithelium in-
fected) as described in the text.
(A) Representative pictures of vaginas from
mice of the indicated genotypes inoculated
with 6 3 105 PFU per mouse.
(B) Scores assigned for vaginas from mice of
the genotypes noted, after inoculation with
HSV-2/Gal at 6 3 105 PFU/mouse. The values
shown are means plus standard deviation
(n = 8–11). Only the mean for the Pvrl/ mice was significantly different from that for the wild-type (+/+) mice (Student’s t test).
(C) Pvrl/ and double mutant mice (Tnfrsf14/Pvrl/) were inoculated with HSV-2/Gal at 6 3 106 PFU per mouse and treated as in (A). A total of
eight double mutant mice have been inoculated with either 6 3 105 or 6 3 106 PFU, and none have exhibited staining scores other than 0 or 1.mice, whereas maximal titers were not detected until day
5 for the Pvrl/ mice. By day 5, maximal titers of virus
were detected in the spinal cords of mice of all three geno-
types but at significantly lower levels for the Pvrl/ mice.
Finally, virus could be detected in the hindbrains of most
wild-type and Tnfrsf14/ mice by days 7 and 9, but not
in any of the Pvrl/ mice. For the DRG and spinal cords
and at time points where infectious virus could be de-
tected in these organs for all wild-type and Tnfrsf14/
mice, there were one or more Pvrl/ mouse in which virus
could not be detected. This study was also done with
Pvrl1+/ mice. Mean titers of virus detected in various
organs of the Pvrl+/ mice at each time point were usually
not statistically different from those obtained for the wild-
type mice but were nevertheless usually less than those
obtained for the wild-type mice, suggesting gene dosage
effects (data not shown), as did Figure 1. Thus, absence of
HVEM expression was without effect on the replication of
HSV-2 in the organs tested, whereas absence of nectin-1
resulted in reduced titers in all organs.
To determine whether replication of HSV-2 could be
detected in double mutant mice, groups of these mice
and control nectin-1-expressing Tnfrsf14/Pvrl1+/ mice
were inoculated with the higher dose of HSV-2 (6 3 106
PFU). Five days after virus inoculation, the mice were sac-
rificed for quantification of progeny virus in homogenates
of vaginas, DRG, and spinal cords. The 5 day time point
was selected because, by this time, input virus that failed
to initiate infection would have been inactivated, and at
this time, mice of all other genotypes had significant levels
of virus in the organs tested (Figure 6). Table 1 shows that,
while significant levels of virus were present in all three
organs of the nectin-1-expressing mice, no virus could
be detected in the double mutant mice (except for a fewCPFU near the lower limit of detection in one vaginal sam-
ple). Thus, double mutant mice may support very low
levels of HSV-2 replication in the vagina (as was noted
also with HSV-2/Gal), but infection did not spread to the
nervous system and did not lead to disease (Figure 2).
DISCUSSION
A major conclusion emerging from this study is that HSV-2
infection of the vaginal epithelium of mice requires ex-
pression of either nectin-1 or HVEM, based on findings
that double mutant Tnfrsf14/Pvrl/ mice were largely
resistant to infection via the vaginal route of inoculation,
whereas both Tnfrsf14/ and Pvrl/ mice were suscep-
tible. Absence of nectin-1 expression reduced the effi-
ciency of infection of the vaginal epithelium, whereas
absence of HVEM expression appeared to be without
effect. Possibly, nectin-1 is normally more accessible or
efficient as an entry receptor than HVEM, at least in the
stratified mouse vaginal epithelium. It was previously re-
ported that nectin-1 mediated infection of the vaginal ep-
ithelium in mice, based on finding that a soluble form of
nectin-1 could reduce or abolish infection (Linehan et al.,
2004). However, this soluble nectin-1 would also be ex-
pected to abolish infection mediated by HVEM. Although
nectin-1 and HVEM bind to different interfaces on gD
(Spear et al., 2006), binding of either soluble receptor to
HSV can inhibit infection of cells bearing either receptor
(Geraghty et al., 1998).
A second major conclusion is that neither HVEM nor
nectin-1 is essential for the spread of HSV-2 infection from
the vaginal epithelium to the nervous system in mice,
based on the detection of infectious HSV-2 and/or b-
galactosidase expressed by HSV-2/Gal in DRG and spinalell Host & Microbe 2, 19–28, July 2007 ª2007 Elsevier Inc. 23
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produced by nonneuronal cells in the vaginal epithelium
could directly enter the endings of neurons that extend
to the epithelium, leading to viral replication in DRG,
whereas replication of virus in the spinal cord would prob-
ably require neuron-to-neuron transmission.
Since replication of HSV-2 in the vaginal epithelium of
double mutant mice was extremely limited, and therefore
HSV-2 access to neurons would be limited, it was not pos-
sible to assess whether HSV-2 could infect neurons via the
vaginal route in these mice. Therefore, a possible role for
another as-yet-unrecognized entry receptor that is ex-
pressed in the nervous system, but not on the vaginal ep-
ithelium, cannot be ruled out. Use of mutant mice in which
receptor expression is knocked out only in neurons could
address this issue.
Clearly, absence of nectin-1, but not HVEM, delayed
and reduced the efficiency of HSV-2 spread to DRG and
Figure 4. Development of Lesions in DRG and the Spinal Cord
after Inoculation of Pvrl/ Mice and Littermate Wild-Type
Mice with HSV-2/Gal
Depo-Provera-treated mice were inoculated with HSV-2/Gal at 63 105
PFU per mouse and sacrificed at days 3, 5, 7, and 9 after inoculation.
The spinal columns were then dissected out (A), the vertebra cut, and
the entire tissue stained with X-gal. After staining, the spinal cords with
attached ganglia and nerves were teased away from other tissue so
that blue foci of infection in these tissues could be scored on a scale
from 0 (no blue stain observed) to 5 (most ganglia in sacral and lumbar
region positive, attached nerves positive, and spinal cord positive in
several regions) as described in the text.
(A) Representative picture of a stained spinal column from a +/+ mouse
sacrificed at day 9. The magnified inset shows two heavily stained and
two lightly stained ganglia in the lumbar region.
(B) Scores assigned for infected mice of the genotypes indicated at the
days indicated. The values shown are means plus standard deviation
(n = 5–7 for the wild-type [+/+] littermate control groups and n = 7 for
allPvrl/groups). Shown in parentheses beside each point in the lower
curve is the number of Pvrl/ mice in each group for which lesions
could be detected in nervous tissue (score greater than 0). On each
day the values for the Pvrl/ mice were significantly different from
those for the +/+ mice (p < or = 0.003, Mann Whitney rank-sum test).
Scale bar divisions in (A) are 0.1 cm.24 Cell Host & Microbe 2, 19–28, July 2007 ª2007 Elsevier Inc.the spinal cord and also delayed and reduced the inci-
dence of mortality. These comparisons were made at an
input dose of virus (6 3 105 PFU) sufficient to infect
virtually 100% of wild-type, Tnfrsf14/, and Pvrl/
mice, but a dose that resulted in reduced involvement of
the vaginal epithelium in Pvrl/ mice. A 10-fold higher
dose of HSV-2/Gal caused greater involvement of the
vaginal epithelium in Pvrl/ mice (Figure 3), but inocula-
tion of HSV-2 at this higher dose did not enhance disease
Figure 5. Development of External Lesions on Skin at Sites
Noncontiguous with the Vaginal Opening and Involvement
of Hair Follicles
(A) A mixed-strain wild-type mouse was treated with Depo-Provera, in-
oculated with 6 3 105 PFU of HSV-2, and photographed on day 15 to
show external hair loss, inflammation, and lesions around the vagina
and rectum. (B–F) A C57BL/6 mouse was treated with Depo-Provera,
inoculated with 63 105 PFU of HSV-2/Gal, and sacrificed 7 days later.
Skin was dissected from the area ventral to the vaginal orifice (vo),
fixed, and stained with X-gal. Areas of skin around the vo suffered
hair loss and had been inflamed. (B) Isolated lesions (blue foci) at sites
distant from the vo. The urethral orifice (uo) is indicated by the arrow.
(C–F) Serial sections, after H&E staining, of paraffin-embedded tissue
from the same mouse. The dark blue insoluble product generated by
action of b-galactosidase on X-gal identifies infected cells on the
epithelial surface of the skin and extending along the hair follicle
toward a sebaceous gland (sg). Scale bar in (C) represents 20 mm for
panels (C)–(F).
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(Figure 6 and Table 1).
A third conclusion is that the formation of external le-
sions, as depicted in Figure 5A, depended on expression
of nectin-1, as these typical lesions were not observed in
Pvrl/ mice. In wild-type or Tnfrsf14/ mice, external
hair loss, inflammation, and lesions were invariably noted
prior to any signs of lethal disease, although not all mice
exhibiting external lesions experienced lethal disease. In
the Pvrl/ mice, on the other hand, the typical external
Figure 6. Viral Loads in Various Tissues of Wild-Type,
Tnfrsf14/, and Pvrl/ Mice at the Days Indicated after
Inoculation with HSV-2
The mice were treated with Depo-Provera, inoculated with HSV-2 at
63 105 PFU per mouse, and sacrificed on the day indicated after inoc-
ulation, and various tissues were removed for preparation of extracts
and virus titrations by plaque assay. Each symbol represents PFU
per g of tissue from an individual mouse. Geometric means for each
experimental group are indicated by horizontal black lines (n = 5–6
for all three genotypes). Symbols in the hatched regions of each panel
represent the lower limit of virus detection; values for these samples
were recorded as the actual low number of PFU detected or assigned
as 0.5 PFU per g of tissue when no PFU were detected. Brackets
marked by an asterisk indicate that means of the viral loads detected
in the +/+ mice were statistically different from those in the mutant
mice (p < 0.05, Student’s t test).Csigns of disease were never observed, at either dose of
virus, even in mice who succumbed to disease and de-
spite levels of virus in various tissues of individual mice
that were comparable to those observed in wild-type
mice (Figure 6). Since the secondary external lesions in
nectin-1-expressing mice are associated with the spread
of virus to perineal skin and surrounding areas, it seems
likely that this spread is somehow blocked in nectin-
1-deficient mice.
It has been established in a flank (zosteriform) model of
HSV disease in mice that secondary lesions occur, begin-
ning about 4 days after inoculation of virus at the primary
site, and that these secondary lesions result from viral
spread via neural pathways and are prevented by neuro-
tomy (Simmons and Nash, 1984). In the vaginal model of
disease, the secondary lesions occurring on the external
skin after primary lesion development in the vaginal epi-
thelium could also depend in part on neural routes of
spread. The isolated microscopic and gross lesions con-
taining HSV-2/Gal at sites noncontiguous to the perivagi-
nal opening (Figure 5) and occurring 5–9 days after virus
inoculation are consistent with a neural route of spread
but do not rule out horizontal cell-cell spread in epithelial
cell layers contiguous from the vaginal mucosa to external
skin (Parr and Parr, 2003). Expression of nectin-1 has been
shown to promote cell-to-cell spread of HSV in nonneuro-
nal cultured cells (Sakisaka et al., 2001). Consistent with
this finding, our results show that (1) lesions on the vaginal
epithelium of nectin-1-deficient mice are smaller than
normal at 24 hr and (2) absence of nectin-1 expression
prevents external lesions that are likely to depend on long-
range cell-to-cell spread of infection, whether this spread
is via neural routes or between contiguous mucosal and
skin epithelia or both.
Whereas absence of nectin-1 expression prevented the
typical external lesions caused by either HSV-2/Gal or
HSV-2, absence of HVEM reduced the incidence of these
lesions, but only for HSV-2/Gal, at least at the virus dose
used in Figure 1. Adoptive transfer of immune cells has
been shown to block zosteriform spread in the mouse flank
model (Simmons and Nash, 1984). Possibly, enhanced
immune responses to an attenuated virus expressing a
bacterial antigen, i.e., HSV-2/Gal, could explain the re-
duced incidence of external lesions in the Tnfrsf14/
mice, compared with wild-type control mice, inasmuch
as absence of HVEM expression has been associated
with enhanced immune responses (Wang et al., 2005).
To what extent are these results relevant to human gen-
ital disease? The three known human entry receptors
for HSV-2 are nectin-1, nectin-2, and HVEM. Human
mutations affecting expression of functional HSV entry re-
ceptors have been described only for nectin-1. Chain-ter-
minating mutations in the Pvrl1 gene have been linked to
an autosomal recessive cleft lip/cleft palate-ectodermal
dysplasia syndrome in a few families from the Margarita
Islands, Brazil, and Israel (Suzuki et al., 2000). Unfortu-
nately, access to persons with disruptions in the nectin-1
gene has been limited, and it has not been determined
whether these people are resistant to HSV infection andell Host & Microbe 2, 19–28, July 2007 ª2007 Elsevier Inc. 25
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Entry Receptors and HSV Disease in MiceTable 1. No Infectious Virus Detected in Dorsal Root Ganglia or Cords of Double Mutant Mice at 5 Days after
HSV-2 Inoculation
Log10 PFU/g of Tissue (Lower Limit of Detection)
a
Mouse Genotype Mouse Number Vagina Dorsal Root Ganglia Spinal Cord
Tnfrsf14/Pvrl1+/ 2438 3.57 4.86 3.40
2439 3.22 4.62 3.67
2441 3.60 4.59 2.62
Tnfrsf14/Pvrl1/ 2440 1.89 (1.42) none (2.49) none (1.17)
2546 none (1.40) none (2.40) none (1.17)
2547 none (1.23) none (2.40) none (1.11)
a Mice of the genotypes indicated were treated with Depo-Provera and 6 days later were inoculated with 63 106 PFU of HSV-2. Five
days after virus inoculation, the mice were sacrificed and the organs indicated were taken to prepare homogenates for titrations of
infectious virus. Virus was undetectable in nervous system tissues of the double mutant mice and in vaginal tissues of two-thirds of
these mice. For all three organs the mean virus titers detected in mice expressing nectin-1 were statistically different from the actual
titer or limits of detection in the double mutant mice (p < 0.005, Student’s t test).disease. The results presented here suggest that they
would not be totally resistant, especially since nectin-2
as well as HVEM could be functional in situ as entry recep-
tors. Nectin-1 is expressed in the human vaginal epithe-
lium throughout the menstrual cycle (Linehan et al., 2004)
and is also expressed in human neurons (Simpson et al.,
2005; Takai et al., 2003). The patterns of expression of
HVEM and nectin-2 have not been well defined in the tis-
sues of relevance to this study. It seems safe to predict
that, as in the mouse, multiple entry receptors could per-
mit infection via the vaginal epithelium and spread to the
nervous system. If, as in the mouse, nectin-1 is required
for secondary mucocutaneous lesions, it may also be re-
quired for recurrent lesions, one of the most troublesome
aspects of HSV disease. Possibly, new approaches to
blocking the interaction of HSV with nectin-1 could be
effective for preventing recurrent disease.
EXPERIMENTAL PROCEDURES
Cells and Virus Strain
Vero cells cultured in Dulbecco’s modification of Eagle’s (DME) me-
dium plus 10% fetal bovine serum (FBS) were used for the propagation
of virus. Plaque titrations were performed on Vero cells by standard
methods. HSV-2 strain 333 was isolated from a genital lesion and un-
derwent limited passage in human cells (Westmoreland and Rapp,
1976). The virus was plaque purified and passaged no more than three
times in Vero cells.
Construction of HSV-2/Gal
HSV-2/Gal has a lacZ expression cassette inserted between the con-
vergently transcribed genes UL3 and UL4. This virus was generated
by cotransfecting Vero cells with genomic DNA from wild-type
HSV-2(333) and plasmid pUL3UL4-CMVlacZ, followed by isolation and
plaque purification of a recombinant virus that expresses b-galactosi-
dase. The insert in the plasmid used for recombination contains the
following elements: nucleotides 11002–11911 from the HSV-2(333)
genome, including the entire UL3 ORF and all but 20 nucleotides of
the downstream UL3-UL4 intergenic region; the immediate-early pro-
moter from human cytomegalovirus (CMV); the lacZ gene; nucleotides
11663–11823 from the HSV-1(KOS) genome, including the entire UL3-
UL4 intergenic region from HSV-1; nucleotides 11932–12531 from the
HSV-2(333) genome, including all but the first few codons of the UL426 Cell Host & Microbe 2, 19–28, July 2007 ª2007 Elsevier Inc.ORF. The intergenic regions, one from HSV-2 and the other from
HSV-1 (different in sequence from the HSV-2 version), were placed up-
stream and downstream of the inserted CMV-lacZ cassette to ensure
that polyadenylation signals would function properly for the UL3, lacZ,
and UL4 transcripts and to avoid homologous recombination between
these repeats. The nucleotide sequences given are from the published
sequences for HSV-1(17) (McGeoch et al., 1988) and HSV-2(HG52)
(Dolan et al., 1998). HSV-2/Gal and HSV-2 were indistinguishable in
levels of UL3 and UL4 expression, as determined by western blot anal-
ysis using antibodies previously described (Yamada et al., 1998, 1999).
Also, HSV-2/Gal was indistinguishable from parental HSV-2 in its abil-
ity to replicate in Vero cells, with respect to the kinetics of progeny pro-
duction and yields of progeny virus during a single replicative cycle. In
wild-type mice, the spread of HSV-2/Gal to various target organs was
similar to that of HSV-2, but HSV-2/Gal was less virulent than HSV-2
(Figure 1). The survival plots for days without lesions and days remain-
ing alive differed significantly (Gehan-Breslow test: p = 0.004 and <
0.001, respectively, for the C57BL/6 mice used as controls for the
backcrossed Tnfrsf14/ mice and p = 0.018 and 0.003, respectively,
for the wild-type littermate mice used as controls for the Pvrl/ mice).
Mouse Lines
Animal care and use were in accordance with institutional and NIH
guidelines, and all studies were approved by the Animal Care and
Use Committee of Northwestern University. Mice were maintained in
specific-pathogen-free conditions until infection and then were trans-
ferred to a containment facility.
Generation of the Tnfrsf14/ mice and backcross to the C57BL/6
background have been described (Wang et al., 2005). The mice used
here were obtained from homozygous mutant breeding pairs and
their genotypes checked by PCR analysis of genomic DNA using for-
ward primer HVEM1 (50-ACTCACAGACACCTACTATGG) and reverse
primers HVEM2 (50-GGAGATGAGTGCTGGAGGAGA) and HVEM
KO (50-CTGAAGAGGAGTTTACGTCCAG). Female C57BL/6 mice, pur-
chased from Jackson Labs, served as wild-type controls for the
Tnfrsf14/ mice.
The generation and properties of Pvrl/ mice were also previously
described (Inagaki et al., 2005). Frozen heterozygous embryos (ge-
netic background 50% 129/SV, 25% C57BL/6, and 25% DBA) at the
two-cell stage were implanted into pseudopregnant C57BL/6 mothers.
The mice obtained were genotyped by PCR analysis of genomic
DNA as previously described (Inagaki et al., 2005). The colony was
maintained by heterozygous mating. Wild-type and Pvrl+/ mice were
used as littermate controls for thePvrl/ mice. Tnfrsf14/ andPvrl/
mice and their progeny were crossed to obtain double mutant mice.
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Female mice ranging in age from 11 to 18 weeks were injected with
0.1 ml of Depo-Provera diluted to 25 mg/ml with phosphate-buffered
saline (PBS) (Parr et al., 1994). Histology performed on the vaginas
of mice sacrificed 6 days after injection showed that, in both wild-
type and mutant mice, Depo-Provera altered the vaginal epithelium,
causing remodeling to noncornified thinned epithelia as described
(Parr et al., 1994). At 6 days after Depo-Provera injection, experimental
mice were anesthetized with tribromoethanol (Papaioannou and Fox,
1993) and then inoculated intravaginally, using a positive-displace-
ment micropipettor, with 20 ml of HSV-2 or HSV-2/Gal diluted in PBS
containing 1% inactivated calf serum and 0.1% glucose. The virus
solution remaining after inoculation was retitered to ensure proper
dosage (6 3 105 or 6 3 106 PFU/mouse). The lower dose was chosen
because, in pilot experiments, 6 3 105 PFU/mouse was shown to
cause 100% incidence of vaginal infection in +/+ mice, as assessed
by staining the vaginal epithelium 24 hr after HSV-2/Gal inoculation,
and >90% incidence of external lesions in +/+ mice after inoculation
with either HSV-2 or HSV-2/Gal. The 10-fold higher dose was the high-
est practical dose that could be administered in attempts to enhance
or detect disease in some of the mutant mice.
Some mice were maintained after inoculation with HSV-2 or HSV-2/
Gal solely to observe and document clinical signs of disease for
21 days or until death or sacrifice. These mice were examined daily
for external lesions (hair loss, inflammation, and skin lesions around
the vaginal opening, rectum, and tail base and down the legs) and
neurological signs of disease (abdominal distention indicative of fecal
or urine retention or, rarely, hind-limb paralysis) or other signs of mor-
bidity (hunched posture, lethargy, dehydration, chills). Those exhibit-
ing severe morbidity were sacrificed. The recorded day of death was
when the mouse was found dead or had to be sacrificed.
Other mice were sacrificed at specific times after virus inoculation
to assess the spread of virus infection to various tissues. For mice in-
oculated with HSV-2/Gal, the vagina and the entire spinal column, as
shown in Figure 4, were removed after sacrifice. The vagina was split
open longitudinally, and the vertebrae of the spinal column were
cut to expose the spinal cord. These organs were fixed in 2% parafor-
maldehyde/0.02% Nonidet-P40 in PBS for 4–6 hr and then stained
overnight with X-gal (solution: 1 mg/ml 5-bromo-4-chloro-3-indolyl-
b-D-galactopyranoside, 3 mM potassium ferrous cyanide, 3 mM ferric
cyanide, 2 mM magnesium chloride, 0.1 mM EGTA, 0.01% sodium
deoxycholate, and 0.02% Nonidet P40). With the aid of a dissecting
microscope, staining of the vaginal luminal surfaces was scored as fol-
lows: 0, no blue staining; 1 = <5 blue foci; 2 = >5 foci, <30% of surface
covered in blue lesions; 3 = >30%, <50%; 4 = >50%, <80%; 5 = >80%
covered in lesions, cervical area infected. Staining of the ganglia, at-
tached nerves, and spinal cords was scored as follows: 0 = no staining;
1 = 2–3 positive ganglia in sacral region only; 2 = 3–5 positive ganglia in
sacral region, nerves positive or negative; 3 = >30% of ganglia positive
in lumbar/sacral region, nerves positive, spinal cord positive or nega-
tive; 4 = >50% of ganglia positive in lumbar/sacral region, nerves pos-
itive, spinal cord positive; 5 = >80% of ganglia positive in lumbar/sacral
region, thoracic ganglia positive or negative, nerves positive, spinal
cord positive in multiple areas.
For mice inoculated with HSV-2, after sacrifice several organs were
removed, weighed, snap frozen, and stored at 80C for virus titration
by plaque assay. The organs were homogenized in 2.5 ml of cold
PBS, 1% calf serum, 0.1% glucose using disposable homogenizers,
sonicated briefly, and centrifuged at low speed to remove tissue de-
bris, and the supernatant was serially diluted for PFU quantification
on Vero cells. Results are presented as PFU per g of tissue.
Histology
C57BL/6, Tnfrsf14/, and Pvrl/ mice (n = 3) were injected with
Depo-Provera as described in the preceding section, and control
mice of each genotype (n = 3) were left untreated. Six days after the
injection, the mice were sacrificed, and vaginas were removed for fix-
ation, embedding in paraffin, and sectioning. The sections wereCstained with H&E. Tissues from mice infected with HSV-2/Gal, includ-
ing external skin stained with X-gal (Figure 5), were also taken for his-
tology to localize the X-gal-stained cells in H&E-stained sections.
Statistical Tests
Kaplan-Meier survival analysis was performed using the Gehan-
Breslow test. Means of scores recorded for X-gal-stained tissues
and geometric means of values for viral infectious units in tissues
were compared using the unpaired Student’s t test or Mann Whitney
rank-sum test.
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